PortalPublikationenHemodynamic improvement following levosimendan treatment in ...

Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.

Standard

Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. / Russ, Martin A; Prondzinsky, Roland; Christoph, Arnd; Schlitt, Axel; Buerke, Ute; Soeffker, Gerold; Lemm, Henning; Swyter, Michael; Wegener, Nikolas; Winkler, Matthias; Carter, Justin M; Reith, Sebastian; Werdan, Karl; Buerke, Michael.

in: CRIT CARE MED, Jahrgang 35, Nr. 12, 12, 2007, S. 2732-2739.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Russ, MA, Prondzinsky, R, Christoph, A, Schlitt, A, Buerke, U, Soeffker, G, Lemm, H, Swyter, M, Wegener, N, Winkler, M, Carter, JM, Reith, S, Werdan, K & Buerke, M 2007, 'Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.', CRIT CARE MED, Jg. 35, Nr. 12, 12, S. 2732-2739. <http://www.ncbi.nlm.nih.gov/pubmed/17893627?dopt=Citation>

APA

Russ, M. A., Prondzinsky, R., Christoph, A., Schlitt, A., Buerke, U., Soeffker, G., Lemm, H., Swyter, M., Wegener, N., Winkler, M., Carter, J. M., Reith, S., Werdan, K., & Buerke, M. (2007). Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. CRIT CARE MED, 35(12), 2732-2739. [12]. http://www.ncbi.nlm.nih.gov/pubmed/17893627?dopt=Citation

Vancouver

Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Soeffker G et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. CRIT CARE MED. 2007;35(12):2732-2739. 12.

Bibtex

@article{e000cbc1e8eb422fb5683bb5075435d1,
title = "Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.",
abstract = "OBJECTIVES: Levosimendan, a novel inodilator, has been shown to improve hemodynamic function in patients with acute exacerbation of congestive heart failure. We wanted to determine the hemodynamic effects of levosimendan following ineffective conventional therapy (with catecholamines) in patients with cardiogenic shock following myocardial infarction. DESIGN: Observational hemodynamic study. SETTING: Tertiary care center university hospital. PATIENTS: Fifty-six patients with cardiogenic shock secondary to myocardial infarction were treated with percutaneous revascularization (intra-aortic balloon pump where appropriate) and commenced on conventional inotropic therapy. INTERVENTIONS: Patients with persisting cardiogenic shock 24 hrs after revascularization were additionally treated with levosimendan (rapid bolus of 12 microg/kg for 10 mins, then 0.05-0.2 mug/kg/min for 24 hrs) (n = 25). MEASUREMENTS AND MAIN RESULTS: With conventional catecholamine therapy (norepinephrine and dobutamine), we observed only marginal improvement in mean arterial pressure or cardiac index. In contrast, the addition of levosimendan produced a significant increase in cardiac index (2.1 +/- 0.56 to 3.0 +/- 1.11 L/min/m2, p <.01) and cardiac power index (0.32 +/- 0.08 to 0.44 +/- 0.18 W, p <.01), whereas systemic vascular resistance decreased significantly (1208 +/- 333 to 858 +/- 299 dyne.sec.cm(-5), p <.01). There was no significant change in blood pressure during levosimendan treatment. Hemodynamic improvement was sustained after levosimendan infusion was stopped. CONCLUSIONS: Levosimendan infusion in cardiogenic shock following acute myocardial infarction improved cardiovascular hemodynamics without leading to hypotension.",
author = "Russ, {Martin A} and Roland Prondzinsky and Arnd Christoph and Axel Schlitt and Ute Buerke and Gerold Soeffker and Henning Lemm and Michael Swyter and Nikolas Wegener and Matthias Winkler and Carter, {Justin M} and Sebastian Reith and Karl Werdan and Michael Buerke",
year = "2007",
language = "Deutsch",
volume = "35",
pages = "2732--2739",
journal = "CRIT CARE MED",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

RIS

TY - JOUR

T1 - Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.

AU - Russ, Martin A

AU - Prondzinsky, Roland

AU - Christoph, Arnd

AU - Schlitt, Axel

AU - Buerke, Ute

AU - Soeffker, Gerold

AU - Lemm, Henning

AU - Swyter, Michael

AU - Wegener, Nikolas

AU - Winkler, Matthias

AU - Carter, Justin M

AU - Reith, Sebastian

AU - Werdan, Karl

AU - Buerke, Michael

PY - 2007

Y1 - 2007

N2 - OBJECTIVES: Levosimendan, a novel inodilator, has been shown to improve hemodynamic function in patients with acute exacerbation of congestive heart failure. We wanted to determine the hemodynamic effects of levosimendan following ineffective conventional therapy (with catecholamines) in patients with cardiogenic shock following myocardial infarction. DESIGN: Observational hemodynamic study. SETTING: Tertiary care center university hospital. PATIENTS: Fifty-six patients with cardiogenic shock secondary to myocardial infarction were treated with percutaneous revascularization (intra-aortic balloon pump where appropriate) and commenced on conventional inotropic therapy. INTERVENTIONS: Patients with persisting cardiogenic shock 24 hrs after revascularization were additionally treated with levosimendan (rapid bolus of 12 microg/kg for 10 mins, then 0.05-0.2 mug/kg/min for 24 hrs) (n = 25). MEASUREMENTS AND MAIN RESULTS: With conventional catecholamine therapy (norepinephrine and dobutamine), we observed only marginal improvement in mean arterial pressure or cardiac index. In contrast, the addition of levosimendan produced a significant increase in cardiac index (2.1 +/- 0.56 to 3.0 +/- 1.11 L/min/m2, p <.01) and cardiac power index (0.32 +/- 0.08 to 0.44 +/- 0.18 W, p <.01), whereas systemic vascular resistance decreased significantly (1208 +/- 333 to 858 +/- 299 dyne.sec.cm(-5), p <.01). There was no significant change in blood pressure during levosimendan treatment. Hemodynamic improvement was sustained after levosimendan infusion was stopped. CONCLUSIONS: Levosimendan infusion in cardiogenic shock following acute myocardial infarction improved cardiovascular hemodynamics without leading to hypotension.

AB - OBJECTIVES: Levosimendan, a novel inodilator, has been shown to improve hemodynamic function in patients with acute exacerbation of congestive heart failure. We wanted to determine the hemodynamic effects of levosimendan following ineffective conventional therapy (with catecholamines) in patients with cardiogenic shock following myocardial infarction. DESIGN: Observational hemodynamic study. SETTING: Tertiary care center university hospital. PATIENTS: Fifty-six patients with cardiogenic shock secondary to myocardial infarction were treated with percutaneous revascularization (intra-aortic balloon pump where appropriate) and commenced on conventional inotropic therapy. INTERVENTIONS: Patients with persisting cardiogenic shock 24 hrs after revascularization were additionally treated with levosimendan (rapid bolus of 12 microg/kg for 10 mins, then 0.05-0.2 mug/kg/min for 24 hrs) (n = 25). MEASUREMENTS AND MAIN RESULTS: With conventional catecholamine therapy (norepinephrine and dobutamine), we observed only marginal improvement in mean arterial pressure or cardiac index. In contrast, the addition of levosimendan produced a significant increase in cardiac index (2.1 +/- 0.56 to 3.0 +/- 1.11 L/min/m2, p <.01) and cardiac power index (0.32 +/- 0.08 to 0.44 +/- 0.18 W, p <.01), whereas systemic vascular resistance decreased significantly (1208 +/- 333 to 858 +/- 299 dyne.sec.cm(-5), p <.01). There was no significant change in blood pressure during levosimendan treatment. Hemodynamic improvement was sustained after levosimendan infusion was stopped. CONCLUSIONS: Levosimendan infusion in cardiogenic shock following acute myocardial infarction improved cardiovascular hemodynamics without leading to hypotension.

M3 - SCORING: Zeitschriftenaufsatz

VL - 35

SP - 2732

EP - 2739

JO - CRIT CARE MED

JF - CRIT CARE MED

SN - 0090-3493

IS - 12

M1 - 12

ER -